Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Annals of internal medicine - 5 May 2015

Linas Benjamin P, Barter Devra M, Morgan Jake R, Pho Mai T, Leff Jared A, Schackman Bruce R, Horsburgh C Robert, Assoumou Sabrina A, Salomon Joshua A, Weinstein Milton C, Freedberg Kenneth A, Kim Arthur Y

Abstract excerpt

BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Liver Cirrhosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Markov Chains

Share to Monte Carlo Method

Share to Quality-Adjusted Life Years

Share to Ribavirin

Share to Sofosbuvir

Share to Uridine Monophosphate

Source

Open in PubMed Open full text

Identifiers

PMID: 25820703
DOI: 10.7326/M14-1313
PMCID: PMC4420667

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.PMID 25820703Read ↗

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Semantic proximity Read ↗

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.Semantic proximity Read ↗

Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan.Semantic proximity Read ↗

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Semantic proximity Read ↗

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.Semantic proximity Read ↗

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.Semantic proximity Read ↗

Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.Semantic proximity Read ↗

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.Semantic proximity Read ↗

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.